Bavarian Nordic boosted by monkeypox vaccine
Bavarian Nordic has sold its monkeypox vaccine for between $70 and more than $300 a dose, according to a person familiar with the matter, pushing the small Danish biotech company close to break-even this year.
Paul Chaplin, president and chief executive, said on Wednesday that these were “exciting times” for the drugmaker as it recorded “all-time high revenues” in the nine months to September. Shares were up 7 per cent after results on Wednesday, having more than doubled since the global monkeypox outbreak started in May.
He was “highly encouraged to see how our vaccines can truly make a difference by providing comfort for the populations at risk and helping to change the course of the monkeypox outbreak”. He declined to comment on the price.
This story originally appeared on: Financial Times - Author:Donato Paolo Mancini
